Previous 10 | Next 10 |
AdaptHealth (NASDAQ: AHCO ) initiated with Buy rating and $17 (31% upside) price target at Stifel. More news on: AdaptHealth Corp., DURECT Corporation, InMed Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Amarin Corporation PLC ( AMRN ) is currently on a roll as the company is gearing up for the expanded market launch of its potential blockbuster drug Vascepa, which is now the only drug approved in the United States for lowering the risk of cardiovascular events in conjunction with statin the...
The following slide deck was published by Arena Pharmaceuticals, Inc. in conjunction with this Read more ...
Arena Pharmaceuticals, Inc. (ARNA) 38th Annual J.P. Morgan Healthcare Conference January 16, 2020 1:00 PM ET Company Participants Amit Munshi – President and Chief Executive Officer Conference Call Participants Yuko Oku – J.P. Morgan Presentation Yuko Oku ...
The FDA designates Arena Pharmaceuticals' (NASDAQ: ARNA ) APD418 for Fast Track review for the treatment of decompensated heart failure (a sudden worsening of signs and symptoms, including difficulty breathing, fatigue and swelling in the legs and feet). More news on: Arena Pharmaceutica...
SAN DIEGO , Jan. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β 3 -adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for t...
SAN DIEGO , Jan. 13, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the appointment of Joan Schmidt as Executive Vice President, General Counsel and Secretary. Ms. Schmidt will join Arena formally in March 2020 and report to Amit D. Mu...
SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, will present a corporate update at the 38 th Annual J.P. Morgan Healthcare Conference on Thursday, Janua...
- Initiation of etrasimod Ph 2/3 program in Crohn's disease (CD) - Two additional Ph 2 etrasimod development programs in eosinophilic esophagitis (EoE) and alopecia areata (AA) - First subject dosed in APD418 Ph 1 trial in Decompensated Heart Failure (DHF) -...
- Selected targets (Project Cabrillo) represent new therapeutic potential across a broad range of immune and inflammatory diseases - Leveraging Beacon's world-class G protein-coupled receptor (GPCR) discovery platform to augment Arena's robust pipeline SAN DIEGO , Jan. 2, 2020...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...